Halozyme, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Laaman from Morgan Stanley upgraded the rating on the stock to a Buy and gave it a $75.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors that highlight Halozyme’s strong financial performance and promising growth prospects. The company reported a significant increase in royalty revenues for the second quarter of 2025, surpassing market expectations by 12%. This growth was driven by the rising demand for Vyvgart Hytrulo and the successful market penetration of Darzalex SC with ENHANZE, which holds a substantial share of the U.S. market.
Furthermore, Halozyme’s strategic initiatives, such as the global expansion of Phesgo and the initiation of a substantial share repurchase program, underscore its commitment to enhancing shareholder value. The company has also raised its financial guidance for the fiscal year 2025, projecting robust growth in total revenues and adjusted EBITDA. These developments have strengthened Morgan Stanley’s confidence in Halozyme’s future growth trajectory, leading to the upgrade in the stock rating.
Laaman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Halozyme, and BioMarin Pharmaceutical. According to TipRanks, Laaman has an average return of 3.4% and a 55.19% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $79.00 price target.